Company Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.
Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome.
Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product.
Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Krish S. Krishnan M.B.A., M.S. |
Contact Details
Address: 2100 Wharton Street Pittsburgh, Pennsylvania United States | |
| Website | https://www.krystalbio.com |
Stock Details
| Ticker Symbol | KRYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001711279 |
| CUSIP Number | 501147102 |
| ISIN Number | US5011471027 |
| Employer ID | 82-1080209 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & Chief Executive Officer |
| Christine Wilson | Head of U.S. Sales & Marketing |
| David Chien | Senior Vice President of Clinical Development |
| Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development |
| John Karakkal | Vice President of North American Sales & Marketing |
| John Thomas | General Counsel & Corporate Secretary |
| Josh Suskin | Director of Human Resources & Operations |
| Kathryn A. Romano CPA | Executive Vice President & Chief Accounting Officer |
| Laurent Goux | Senior Vice President & GM of Europe |
| Suma M. Krishnan | Founder, President of R&D and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 13, 2024 | 4 | Filing |